Ancora Founder Peter Seeberger Receives Claude S. Hudson Award in Carbohydrate Chemistry
News Apr 07, 2009
Ancora Pharmaceuticals co-founder and scientific advisor Peter Seeberger has been awarded the “Claude S. Hudson Award in Carbohydrate Chemistry” for his development of an automated carbohydrate synthesizer.
Seeberger accepted the award, along with presenting his paper on the research, CARB 004, at the National Meeting of the American Chemical Society being held in Salt Lake City this week.
Seeberger spoke at the meeting, reporting a major advance in creating carbohydrate-based vaccines. “Instead of years, the carbohydrates that may form the basis of revolutionary new vaccines and drugs to battle diseases such as malaria, HIV, neurological and cardiovascular diseases, now can be precisely synthesized to scale in a fraction of that time,” he said. “Ancora’s automated synthesizer is now one of the fastest methods to create complex carbohydrates.”
Ancora Pharmaceuticals, in collaboration with Prof. Seeberger’s lab at the Max Planck Institute in Berlin, is using the carbohydrate synthesizer to discover and develop over a dozen vaccine candidates targeting some of today’s most serious antibiotic resistant infectious diseases. The most advanced candidate, a malaria vaccine, is in late-stage preclinical development and is headed for clinical trials by 2011.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018